---
title: "Sinobioway Medicine plans to sign a sales contract with Jiangsu Suhao, with a total contract price of 53.978 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/231529652.md"
description: "Sinobioway Medicine's wholly-owned subsidiary Shandong Yandu Biotechnology Co., Ltd. plans to sign a sales contract with Jiangsu Suhao Innovation Technology Group Co., Ltd., with a total contract price of 53.978 million yuan, mainly for the procurement of equipment and materials needed for the biopharmaceutical industrial park project"
datetime: "2025-03-12T11:49:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/231529652.md)
  - [en](https://longbridge.com/en/news/231529652.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/231529652.md)
generator: "portal-rs"
---

# Sinobioway Medicine plans to sign a sales contract with Jiangsu Suhao, with a total contract price of 53.978 million yuan

According to the Zhitong Finance APP, Sinobioway Medicine (002581.SZ) announced that its wholly-owned subsidiary Shandong Yandu Biotechnology Co., Ltd. ("Shandong Yandu") plans to sign a "Sales Contract" with Jiangsu Suhao Innovation Technology Group Co., Ltd. ("Jiangsu Suhao") to procure the necessary 配储液系统 and chromatography systems, fillers, and reaction bags for the reconstruction of the human nerve growth factor eye drop production workshop at the Shandong Sinobioway Biomedical Industrial Park project, with a total contract price of 53.978 million yuan

### Related Stocks

- [002581.CN](https://longbridge.com/en/quote/002581.CN.md)
- [C76.SG](https://longbridge.com/en/quote/C76.SG.md)

## Related News & Research

- [HBC: Break-even operational EBITDA and premium pricing drove margin gains despite lower volumes](https://longbridge.com/en/news/296575295.md)
- [Motor racing-Verstappen commits to Red Bull until end of 2030](https://longbridge.com/en/news/296454611.md)
- [Danantara Sumberdaya Indonesia is identifying commodity export inconsistencies, chief says](https://longbridge.com/en/news/296773364.md)
- [Flexcon Announces Global Relaunch of PharmCal® BioMark with ISEGA Certification](https://longbridge.com/en/news/296800649.md)
- [Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate](https://longbridge.com/en/news/296689195.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**